N4P N4 Pharma Plc

TIDMN4P

RNS Number : 2398N

N4 Pharma PLC

18 May 2020

18 May 2020

N4 Pharma Plc

("N4 Pharma" or the "Company")

Patent filing update

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, provides an update on its patent application for Nuvec(R), filed in November 2018 (no. PCT/GB2018/053298).

As announced on 15 November 2018, the Company filed a Patent Cooperation Treaty ("PCT") patent application for improvements made to the manufacturing process for its Nuvec(R) system. Under the terms of the PCT application process and following conclusion of the national phasing, the Company is now required to make specific applications in the territories in which it wishes to gain patent protection.

In consideration of this, the Company is filing ongoing patent applications in the following territories: Europe (including the UK); USA; Japan; India; Australia; Canada; and China. These additional applications, if successful, claim priority from the Company's United Kingdom patent application number 1718817.8.

Nigel Theobald, Chief Executive Officer of the Company, commented:

"We are seeking additional protection in the territories listed above, which the Board believes would provide maximum patent coverage for our PCT application whilst minimising outgoing expenditure. If the patents are granted in these regions, the Company will maintain its strong commercial protection of Nuvec (R) ."

Enquiries:

 
 N4 Pharma Plc 
  Nigel Theobald, CEO         Via Scott PR 
 Allenby Capital Limited    Tel: +44(0)203 328 5656 
  James Reeve/Asha Chotai 
 Turner Pope Investments    Tel: +44(0)20 3657 0050 
  (TPI) Ltd 
  Andrew Thacker 
 Scott PR 
  Georgia Smith               Tel: +44(0)1477 539 539 
 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec(R).

N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

UPDSFLFDAESSEEI

(END) Dow Jones Newswires

May 18, 2020 09:25 ET (13:25 GMT)

N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jul 2023 bis Jul 2024